E-cadherin genetic variants predict survival outcome in breast cancer patients
© The Author(s) 2016
Received: 29 August 2016
Accepted: 8 November 2016
Published: 16 November 2016
E-cadherin is a major component of adherens junctions that regulates cell shape and maintains tissue integrity. A complete loss or any decrease in cell surface expression of E-cadherin will interfere with the cell-to-cell junctions’ strength and leads to cell detachment and escape from the primary tumor site. In this prospective study, three functional single nucleotide polymorphisms (−347G/GA, rs5030625; −160C/A, rs16260; +54C/T, rs1801026), were found to modulate E-cadherin expression.
577 DNA samples from breast cancer (BC) cases were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP).
We detected no significant correlations between each polymorphism and the clinical parameters of the patients whereas the GACC haplotype was significantly associated with low SBR grading. Overall survival analysis showed that both −347G/G and +54C/C wild (wt) genotypes had a significantly worse effect compared to the other genotypes (non-wt). Moreover, carrying simultaneously both the −347 and +54 wt genotypes confers a significantly higher risk of death. However, with metastatic recurrence, the death-rate was null in patients carrying the non-wt genotypes, and attained 37% in those carrying the wt genotype. A multivariate analysis showed that these two polymorphisms are independent prognostic factors for overall survival in BC patients.
Our results support the fact that E-cadherin genetic variants control disease severity and progression and could be a marker of disease outcome. These findings could be useful in selecting patients that should be monitored differently.
KeywordsE-cadherin SNP Prognosis Breast cancer
In 2012, one out of four cancer cases is a breast cancer (BC) case . In North African countries BC is also the commonest cancer among women, and the incidence rates are widely lower than in European Mediterranean countries . The incidence is probably underestimated in these developing countries because of the difficulties related to screening and diagnostic programs. However, considering death rates, BC is the second cause of cancer death in more developed regions (198,000 deaths) and remains the most frequent in less developed regions (324,000 deaths). Yet, whatever socioeconomic status, it is well known that BC is a multifactorial disease, and that besides environment and lifestyle, the genetic background contributes to the increase of the risk of having breast cancer. While a huge amount of studies reported the involvement of genes, genetic loci or genetic polymorphisms in breast cancer susceptibility, studies of the genetic influence on disease progression and severity are less frequent . Defining in gene-candidates, single nucleotide polymorphisms (SNPs) associated with increased severity or worsening progression of BC will potentially allow a better individualized handling of patients and as well as a better understanding of the mechanisms of cancer progression [4–6].
BC recurrence or metastasis represents the main cause of breast cancer-related deaths. It has been shown that epithelial-mesenchymal transition (EMT), a process by which epithelial cells acquire mesenchymal stem cell proprieties, plays a critical role in promoting metastasis in carcinomas . One of the initiating steps of EMT involves downregulation and relocation of the main epithelial cell adhesion protein, the epithelial-cadherin (E-cadherin) . In normal epithelial tissues, E-cadherin is a major component of adherens junctions that regulates cell shape and maintains tissue integrity . A complete loss of E-cadherin expression/function or any decrease in cell surface expression, caused by mutation of the CDH1 gene, or other mechanisms that decrease E-cadherin expression will interfere with the cell-to-cell junctions’ strength and leads, inter alia, to cell detachment and escape from the primary tumor site. The CDH1 gene (OMIM 192090) is located on chromosome 16q22, several single nucleotide polymorphisms (SNP) localized in non-coding sequences and affecting protein expression were described. The −347G/GA (rs5030625) and −160C/A (rs16260) SNPs within the promoter region are the most extensively studied CDH1-SNPs in disease association studies. Both the minor alleles were previously shown to reduce E-cadherin expression by affecting the transcriptional efficiency of the CDH1 gene. The −347GA allele has weak transcriptional factor-binding strength and transcriptional activity compared with that of the G allele , while the −160A allele decreases the transcriptional efficiency compared with that of the C allele . Additional regulatory polymorphisms outside of the promoter region that influence E-cadherin expression have also been reported. The +54C/T (rs1801026) is located at 141 bp upstream of the poly-A signal in the 3′-UTR region. The study of Jacobs et al. showed that the occurrence of the T allele is related to a lower mRNA stability and also a reduced luciferase expression by a reporter gene constructs driven by a constitutive SV40-promoter . In regards to breast cancer, few investigations have been carried out on the association between CDH1 polymorphisms and cancer severity or progression. This is why in this prospective cohort study conducted on 577 sporadic BC cases, three functional SNPs from of the E-cadherin gene (CDH1) were genotyped, and the possible prognostic values of these genetic variations were investigated.
Clinical characteristics of breast cancer patients
Age at diagnosis
Lymph node involvement
Genomic DNA extraction and SNP genotyping analysis
Genomic DNA was extracted from peripheral blood leukocytes by a “salting out” procedure . Briefly, 10 ml of blood was mixed with Triton lysis buffer (0.32 M sucrose, 1% Triton X-100, 5 mM MgCl2, 10 mM Tris–HCl, pH 7.5). The pellet was incubated with proteinase K at 56 °C and subsequently salted out using a saturated NaCl solution. Precipitated proteins were removed by centrifugation. The DNA in supernatant fluid was precipitated with ethanol. Finally, the DNA pellet was conserved in Tris–EDTA buffer. DNA concentration and quality were analyzed by thermo-scientific NanoDrop 2000™.
Primers and restriction enzymes used for polymorphism genotyping
Fragments size (bp)
G: 263 + 116 + 68
GA: 332 + 116
C: 181 + 177 + 89
A: 266 + 181
C: 146 + 26
To evaluate if our study population (patients and controls) is in the Hardy–Weinberg equilibrium we used the Chi square test to compare between observed and expected genotype frequencies of CDH1 gene polymorphisms. The same test was used to evaluate any significant association between the three CDH1 polymorphisms and the clinicopathological characteristics of the disease. The differences were considered significant if the p value did not exceed 0.05. Odd ratios (ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression. When expected values in contingency tables were under 5, Fisher’s exact test was used. The LD between SNPs pairs was quantified using the standardized linkage disequilibrium coefficient (D’) . The haplotypes and their frequencies were estimated using the Phase program .
Disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) were calculated using the Kaplan–Meier method for ten years and compared with the log-rank test. DFS was defined as the date of diagnosis until first recurrence, metastasis, death due to breast cancer or the last date of follow-up. MFS was defined as the date of diagnosis until first metastasis or last date of follow-up and OS was defined as the date of diagnosis until death due to breast cancer or last date of follow-up. Variables with a p-value less than 0.1 in the univariate Cox regression model were evaluated in a multivariate Cox regression model using the enter method. Because of the low number of the cases with metastasis at diagnosis (n = 10) we choose to exclude the metastasis parameter from the haplotypes and multivariate analysis. All statistics were carried out using Software Package for Social Sciences (SPSS) version 20.0 (SPSS, Chicago, IL, USA).
CDH1 SNPs and their association with clinicopathological characteristics of breast cancer patients
All DNA samples were successfully genotyped for the three CHD1 SNPs (577 patients and 300 controls). For both patient and control groups all genotype distributions did not diverge significantly from Hardy–Weinberg equilibrium. Moreover, the minor allele frequencies (MAF) of these variants in the control population were close to those reported in Europeans (HapMap consortium) (−347GA: 0.150; −160A: 0.322 and +54T: 0.206). Among the patients, the −347G/GA genotype frequencies were 72.4% for GG, 24.8% for GGA and 2.8% for GAGA. For the −160C/A SNP, genotype frequencies were 45.9% for CC, 43.7% for CA and 10.4% for AA. The +54C/T genotype frequencies were 35.6% for CC, 47.1% for CT and 17.3% for TT.
Correlation between CDH1 SNPs and clinicopathological characteristics of breast cancer patients
GGA + GAGA
OR (95% CI)
CA + AA
OR (95% CI)
CT + TT
OR (95% CI)
Age at diagnosis
Lymph node involvement
Haplotype frequencies of CDH1 SNPs observed in breast cancer patients and controls
Correlation between CDH1 haplotype frequencies and clinicopathological characteristics of breast cancer patients
GAAC and GAAT
Age at diagnosis
OR (CI 95%)
OR (CI 95%)
OR (CI 95%)
Lymph node involvement
OR (CI 95%)
OR (CI 95%)
OR (CI 95%)
CDH1 SNPs and clinicopathological characteristics associated with survival in patients with breast cancer
Clinicopathological characteristics associated with disease-free survival and overall survival in patients with breast cancer
Lymph node involvementd
CDH1 −347 G/GA g
CDH1 −160 C/A g
CDH1 +54 C/T g
Previous studies have shown that the development and the progression of epithelial cancers such as BC are related to the loss or the reduced expression of the main intercellular adhesion molecule of epithelial cells, the E-cadherin. The loss of cell-to-cell adhesion is an early event in metastatic colonization, leading to the detachment of the cell from her tissue of origin to colonize other sites.
E-cadherin expression is under the control of functional SNPs. As far as we know, reports were mainly case control-studies looking for risk of developing BC, and very few studies with controversial results were investigated to identify the relationship between CDH1 genetic variants and clinicopathological features of the patients. In our study, none of the studied SNPs showed any significant correlations with patients’ epidemiological or tumor or histological features. Shabnaz et al. also did not find any correlation between −160C/A polymorphisms with clinicopathological characteristics of BC patients . However, Tipirisetti et al. noted a positive correlation between the −160A allele occurrences in patients with advanced stage . In a Taiwanese study conducted on hepatocellular carcinoma patients, the occurrence of the −160A allele was significantly associated with more severe clinical stages . Conversely, in a recent study of pancreatic cancer cases, the −160AA genotype was found to be significantly associated with reduced risk with T stage, lymph node metastasis and pathological stage . In accordance with the previous results, a Japanese study of gastric cancer cases found that the −160CC genotype was significantly associated with deep invasion and lymph node metastasis . Although previous studies were conducted mainly on epithelial cancer cases, a possible explanation of these contrasting results is the occurrence of one or more other SNPs, found in strong LD with the −160C/A in some ethnic groups (e.g. rs7200690, rs9929218). Further studies should be conducted among different ethnic groups to help understanding these results.
To see the combined effects of the three functional SNPs the haplotype analysis was investigated. Weak LD values, generally associated with higher recombination rates, were observed among patients . Conversely, stronger LD values were observed among controls, suggesting a possible protective effect of the strong LD against BC. However, further investigations with a larger control sample size are needed to explain this result. To the best of our knowledge, this is the only study that explored the relationship between CDH1 haplotype frequencies and tumor severity. The −347GA − 160C + 54C haplotype may have a protective effect against high SBR grading. This haplotype has only one mutated allele at the −347 position, whilst having protective effect, however, the GA allelic analysis did not show significant differences with the G allele when patients were compared according to SBR grading (p = 0.12, OR = 0.75). Although each SNP had a functional impact on E-cadherin expression, the effects of their interactions and combinations are unknown, hence there is a need for further studies to describe the functionality of haplotypes including these three SNPs.
Moreover, very few studies investigated the associations of the CDH1 SNPs with patient survival. In a recent study conducted on a Chinese population, Jia et al. showed that BC patients with low clinical tumor stages and carrying the minor allele genotype of an SNP (rs7200690) located in intron 2 in strong LD with the −160C/A SNP, had unfavorable disease-free survival . However, in a British population-based study no effect of the −160C/A SNP was seen on BC survival . In the present study the −347G/GA and +54C/T SNPs, but not the −160C/A SNP, were shown to be associated with BC overall survival. When considering the whole patient group, both wild genotypes were shown to be associated with worse BC overall survival. Moreover, patients carrying simultaneously the wild genotypes, −347G/G and +54C/C, had worse survival rates than those carrying one of each genotype. Interestingly, when considering more aggressive tumor subgroups (T3–T4, lymph node positive, high grade SBR and metastasis occurrence after treatment) we observed significantly worse survival rates with the −347G/G genotype and a decrease in survival when patients carry simultaneously the −347G/G and +54C/C genotypes. Herein we found that the CDH1 −347G/G genotype confer risk of death in patients with more aggressive BC progression.
It is well known that in normal epithelial tissues, E-cadherin expression has suppressive effects on tumor progression, invasion and metastasis and thus any deregulation of E-cadherin expression could have critical pathological consequences. In a pathological context, E-cadherin expression could be modulated by several mechanisms, loss of heterozygosity, mutations of the CDH1 gene, epigenetic modulation, proteolytic processing and also cadherin switching . In BC, studies on E-cadherin tissue expression were conflicting. Most of them showed that reduced or loss of E-cadherin expression correlates with high histological grade, larger tumor size, nodal metastasis, development of distant metastasis, and a reduced disease-free and overall survival [26–28]. However, in recent reports the involvement of E-cadherin in breast cancer severity and progression has increasingly been suggested [29, 30]. The ambiguous role of E-cadherin could be partially due to the existence of at least two different and functional forms of E-cadherin, a full-length membrane form and an extracellular proteolytic soluble form (sE-cad). During the oncogenic process the first consequence of the E-cadherin proteolysis is the cell detachment and the release of a functional sE-cad with cancer promoting functions. Inside the tumor microenvironment, sE-cad inhibits cell-to-cell adhesion through an efficient competitive manner and by stimulating the activity of multiple matrix metalloproteinases (MMPs) . Then, when sE-cad diffuse and spread into blood circulation, multiple oncogenic signaling pathways are activated [32, 33]. Recently, Liang et al., assessed the clinical significance of serum sE-cad levels in BC patients. They observed a significant correlation of sE-cad levels with tumor stage, grade, lymph node metastasis and also survival . Moreover, Hofmann et al., found that serum sE-cad levels might be a marker predicting response to preoperative chemotherapy for patients with locally advanced breast cancer . Functional SNPs modulate the expression of both the membrane and the soluble E-cadherin forms in the same way. Since the two forms play opposite functions, the membrane form expressed in normal tissue acts as a tumor suppressor, while the soluble form associated with disease severity promotes tumor progression, this could explain why patients expected to have reduced E-cadherin expression have better survival whatever the severity of the disease.
This study provides novel information about the relationship between E-cadherin (CDH1) genetic variants and clinicopathological features and progression of BC. The main finding of this study is the association of CDH1 functional SNPs with overall survival in BC, particularly in patients with a more aggressive tumor at onset or with recurrent metastatic BC. Our results support the fact that the CDH1 SNPs control disease severity and progression and could be a marker of disease outcome. These findings could be useful in selecting patients who should be monitored differently. Additional investigations on functional evaluation of CDH1 SNPs should be carried out to support our findings.
polymerase chain reaction-restriction fragment length polymorphism
single nucleotide polymorphism
- CDH1 :
95% confidence intervals
multiple matrix metalloproteinases
HE, CL and ZA designed the study. MH, KZ, MY, RY, GS, MW, BN and BN helped in sample collection. MH assessed the molecular genotyping. KZ, MY, RY, HE, NB and NB generated the data. HE, MY, FK and B-H-AA analyzed the data. HE wrote the manuscript. All authors read and approved the final manuscript.
This work was supported by the Ministry of Higher Education and Scientific Research and by the Ministry of Health of the Republic of Tunisia. We thank Mr Adel Rdissi for English revision.
The authors declare that they have no competing interests.
Availability of data and materials
All the data presented is available upon request.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the National Ethical Committee.
The Ministry of Higher Education and Scientific Research have supported this work.
A written informed consent was obtained from all enrolled individuals prior to their participation.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.View ArticlePubMedGoogle Scholar
- Giordano L, Bisanti L, Salamina G, Ancelle Park R, Sancho-Garnier H, Espinas J, Berling C, Rennert G, Castagno R, Dotti M, Jaramillo L, Segnan N, Euromed Cancer Working Group. The EUROMED CANCER network: state-of-art of cancer screening programmes in non-EU Mediterranean countries. Eur J Public Health. 2016;26:83–9.View ArticlePubMedGoogle Scholar
- Shan J, Mahfoudh W, Dsouza SP, Hassen E, Bouaouina N, Abdelhak S, Benhadjayed A, Memmi H, Mathew RA, Aigha II, Gabbouj S, Remadi Y, Chouchane L. Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs:susceptibility and prognostic implications in Tunisians. Breast Cancer Res Treat. 2012;135:715–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer. 2001;91:672–8.View ArticlePubMedGoogle Scholar
- Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ahmed SB, Chouchane L. Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer. 2008;8:109.View ArticlePubMedPubMed CentralGoogle Scholar
- Snoussi K, Mahfoudh W, Bouaouina N, Fekih M, Khairi H, Helal AN, Chouchane L. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer. 2010;10:283.View ArticlePubMedPubMed CentralGoogle Scholar
- Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27:2192–206.View ArticlePubMedPubMed CentralGoogle Scholar
- Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.View ArticlePubMedGoogle Scholar
- Van Roy F, Berx G. The cell–cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65:3756–88.View ArticlePubMedGoogle Scholar
- Shin Y, Kim IJ, Kang HC, Park JH, Park HR, Park HW, Park MA, Lee JS, Yoon KA, Ku JL, Park JG. The E-cadherin −347G−>GA promoter polymorphism and its effect on transcriptional regulation. Carcinogenesis. 2004;25:895–9.View ArticlePubMedGoogle Scholar
- Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, Nojima D, Carroll P, Dahiya R. A single nucleotide polymorphism in the E-cadherin gene promoteralters transcriptional activities. Cancer Res. 2000;60:873–6.PubMedGoogle Scholar
- Jacobs G, Hellmig S, Huse K, Titz A, Franke A, Kwiatkowski R, Ott S, Kosmahl M, Fischbach W, Lucius R, Klapper W, Fölsch UR, Hampe J, Schreiber S, Rosenstiel P. Polymorphisms in the 3′-untranslated region of the CDH1 gene are a risk factor for primary gastric diffuse large B-cell lymphoma. Haematologica. 2011;96:987–95.View ArticlePubMedPubMed CentralGoogle Scholar
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.View ArticlePubMedPubMed CentralGoogle Scholar
- Kiemeney LA, van Houwelingen KP, Bogaerts M, Witjes JA, Swinkels DW, denHeijer M, Franke B, Schalken JA, Verhaegh GW. Polymorphisms in the E-cadherin(CDH1) gene promoter and the risk of bladder cancer. Eur J Cancer. 2006;42:3219–27.View ArticlePubMedGoogle Scholar
- Zhang XF, Wang YM, Ge H, Cao YY, Chen ZF, Wen DG, Guo W, Wang N, Li Y, ZhangJ H. Association of CDH1 single nucleotide polymorphisms with susceptibility toesophageal squamous cell carcinomas and gastric cardia carcinomas. Dis Esophagus. 2008;21:21–9.View ArticlePubMedGoogle Scholar
- Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97–8.View ArticlePubMedGoogle Scholar
- Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978–89.View ArticlePubMedPubMed CentralGoogle Scholar
- Shabnaz S, Ahmed MU, Islam MS, Islam MR, Al-Mamun MM, Islam MS, Hasnat A. Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women. Tumour Biol. 2016;37:7229–37.View ArticlePubMedGoogle Scholar
- Tipirisetti NR, Govatati S, Govatati S, Kandukuri LR, Cingeetham A, Singh L, Digumarti RR, Bhanoori M, Satti V. Association of E-cadherin single-nucleotide polymorphisms with the increased risk of breast cancer: a study in South Indian women. Genet Test Mol Biomarkers. 2013;17:494–500.View ArticlePubMedGoogle Scholar
- Chien MH, Yeh KT, Li YC, Hsieh YH, Lin CH, Weng MS, Kuo WH, Yang SF. Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma. J Surg Oncol. 2011;104:299–304.View ArticlePubMedGoogle Scholar
- Zhao L, Wang YX, Xi M, Liu SL, Zhang P, Luo LL, Liu MZ. Association between E-cadherin (CDH1) polymorphisms and pancreatic cancer risk in Han Chinese population. Int J Clin Exp Pathol. 2015;8:5753–60.PubMedPubMed CentralGoogle Scholar
- Kuraoka K, Oue N, Yokozaki H, Kitadai Y, Ito R, Nakayama H, Yasui W. Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. Int J Oncol. 2003;23:421–7.PubMedGoogle Scholar
- Ardlie KG, Kruglyak L, Seielstad M. Patterns of linkage disequilibrium in the human genome. Nat Rev Genet. 2002;3:299–309.View ArticlePubMedGoogle Scholar
- Jia YM, Xie YT, Wang YJ, Han JY, Tian XX, Fang WG. Association of genetic polymorphisms in CDH1 and CTNNB1 with breast cancer susceptibility and patients’ prognosis among Chinese han women. PLoS ONE. 2015;10:e0135865.View ArticlePubMedPubMed CentralGoogle Scholar
- Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF, Pharoah PP. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 2002;62:3052–7.PubMedGoogle Scholar
- Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53:1696–701.PubMedGoogle Scholar
- Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. ReducedE-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol. 1996;105:394–402.View ArticlePubMedGoogle Scholar
- Hunt NC, Douglas-Jones AG, Jasani B, Morgan JM, Pignatelli M. Loss of E-cadherin expression associated with lymph node metastases in small breast carcinomas. Virchows Arch. 1997;430:285–9.View ArticlePubMedGoogle Scholar
- Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003;5:R217–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. E-cadherin’s dark side: possible role in tumor progression. Biochim Biophys Acta. 2012;1826:23–31.PubMedPubMed CentralGoogle Scholar
- Nawrocki-Raby B, Gilles C, Polette M, Bruyneel E, Laronze JY, Bonnet N, Foidart JM, Mareel M, Birembaut P. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer. 2003;105:790–5.View ArticlePubMedGoogle Scholar
- Brouxhon SM, Kyrkanides S, Teng X, Raja V, O’Banion MK, Clarke R, Byers S, Silberfeld A, Tornos C, Ma L. Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of theHER/PI3K/Akt/mTOR and IAP pathways. Clin Cancer Res. 2013;19:3234–46.View ArticlePubMedPubMed CentralGoogle Scholar
- Brouxhon SM, Kyrkanides S, Teng X, Athar M, Ghazizadeh S, Simon M, O’Banion MK, Ma L. Soluble E-cadherin: a critical oncogene modulating receptor tyrosinekinases, MAPK and PI3K/Akt/mTOR signaling. Oncogene. 2014;33:225–35.View ArticlePubMedGoogle Scholar
- Liang Z, Sun XY, Xu LC, Fu RZ. Abnormal expression of serum soluble E-cadherin is correlated with clinicopathological features and prognosis of breast cancer. Med Sci Monit. 2014;20:2776–82.PubMedPubMed CentralGoogle Scholar
- Hofmann G, Balic M, Dandachi N, Resel M, Schippinger W, Regitnig P, Samonigg H, Bauernhofer T. The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy. Clin Biochem. 2013;46:1585–9.View ArticlePubMedGoogle Scholar